Cell and Gene Outsourcing

  1. CDMO Selection: Start With The Relationship, Not The RFP 6/1/2026

    Friction often comes from unspoken expectations. Before production begins, treat the combined sponsor-CDMO group as one extended team and intentionally make “how we work together” visible.

  2. IDT Biologika Capabilities Update May 2026: Mammalian Cell Culture 5/29/2026

    This webinar provides an expert overview of how IDT Biologika leverages advanced mammalian cell culture platforms to enable efficient, scalable biopharmaceutical development and manufacturing.

  3. Resilience Capabilities Update May 2026: Large Molecule 5/29/2026

    An integrated network unites biologics, cell therapy, and drug product with digital systems and teams to speed tech transfer, scale reliably, and ensure delivery from development to commercial.

  4. Rentschler Biopharma Capabilities Update May 2026: Large Molecule 5/29/2026

    Rentschler Biopharma is a global leading contract development and manufacturing organization (CDMO) focused exclusively on client projects. 

  5. Why Risk Analysis And Lane Qualification Matter 5/28/2026

    Risk analysis and lane qualification show supply chains perform consistently, meeting regulatory expectations by demonstrating control, reducing variability, and ensuring reliable delivery.

  6. The Cornerstones Of Cell Therapy Excellence 5/28/2026

    Cell therapy success relies on integrated analytics, process development, quality, and manufacturing, using risk management and DoE strategies to ensure scalable, compliant, cost-effective delivery.

  7. Navigating Intensifying Cell Therapy Regulatory Expectations 5/28/2026

    Rising regulatory demands require strong CMC, validated analytics, and inspection-ready operations. Early alignment of quality, scalability, and risk management is key to cell therapy commercialization.

  8. Expanding To Develop And Deliver Tomorrow's Cures 5/28/2026

    Facility expansion boosts cleanroom capacity and capabilities, enabling scalable manufacturing, faster tech transfer, and better support for clinical and commercial cell therapies.

  9. Integrate Cryopreservation Into the End-To-End Supply Chain 5/28/2026

    Cryopreservation should be integrated across the entire supply chain to ensure traceability, reduce risk at handoffs, and support consistent, scalable therapy development and delivery.

  10. Setting A New Standard For Biotech Program Visibility 5/27/2026

    Biotech visibility improves through real-time data and centralized platforms, enabling collaboration, faster decisions, reduced risk, and better partner alignment.